Results 91 to 100 of about 14,491 (226)

Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicenter retrospective study

BMC Medicine, 2022
Background Central nervous system (CNS) metastases in patients with ALK-positive non-small cell lung cancer (NSCLC) are a cause of substantial morbidity and mortality.
Zihua Zou, Puyuan Xing, Xuezhi Hao, Yan Wang, Xia Song, Li Shan, Cuiying Zhang, Ziling Liu, Kewei Ma, Guilan Dong, Junling Li   +10 more
doaj   +1 more source

Radioresistant but Alectinib‐Responsive Isolated Intramedullary ALK‐Positive Histiocytosis

Case Reports in Hematology, Volume 2026, Issue 1, 2026.
A 56‐year‐old woman with a history of C4–C5 myelomeningocele repair as a newborn and cervical syringomyelia presented with one week of rapidly worsening bilateral lower extremity weakness and numbness, saddle anesthesia, and bladder incontinence. MRI of the entire spine revealed a 1.5 × 0.5 cm homogenously enhancing intramedullary lesion at T7–T8 with ...
Joshua Van Allen, David Raggay, Brendan Killory, Joseph DiGiuseppe, Mark Dailey, Carlos Cruz-Montecinos   +5 more
wiley   +1 more source

Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer

npj Precision Oncology
Targeting the drug tolerant persister (DTP) state in cancer cells should prevent further development of resistance mechanisms. This study explored combination therapies to inhibit alectinib-induced DTP cell formation from anaplastic lymphoma kinase ...
Takaaki Fujimura, Koh Furugaki, Hayato Mizuta, Satoshi Muraoka, Makoto Nishio, Jun Adachi, Ken Uchibori, Eisaku Miyauchi, Hidetoshi Hayashi, Ryohei Katayama, Shigeki Yoshiura   +10 more
doaj   +1 more source

Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib [PDF]

, 2020
Aim: To estimate management cost of NSCLC ALK+ patients with and without brain metastasis (BM), and to compare annual costs in patients treated with alectinib or crizotinib.
de Alda, L. R., Gordo, R., Isla, D., Lazaro Quintela, Mart?n, Massuti, B., Ortega-Joaqu?n, N., Oyag?ez, I.   +6 more
core   +1 more source

Prognostic Analysis of Lung Cancer With Brain Metastases in Elderly Patients: A Multicenter Retrospective Study

AGING MEDICINE, Volume 8, Issue 6, Page 585-591, December 2025.
Targeted therapy is associated with significantly improved prognosis and longer OS in elderly lung cancer brain metastases patients. And neurosurgical resection, radiotherapy, immunotherapy, and chemotherapy do not significantly affect OS in this patient group.
Anqi Li, Daqin Feng, Chang Liu, Chaojue Huang, Tang Li, Donggui Wei, Fangyi Wei, Muling Shen, Congzhi Qin, Shufang Deng, Hui Liang, Panlin Mo, Minhai Dong, Yongjia Yu, Lun Liang   +14 more
wiley   +1 more source

Next‐Generation Proteolysis‐Targeting Chimeras in Precision Oncology: Multifunctional Designs, Emerging Modalities, and Translational Prospects in Targeted Protein Degradation

Drug Development Research, Volume 86, Issue 8, December 2025.
ABSTRACT Proteolysis‐targeting chimeras (PROTACs)‐mediated protein degradation has been recently developed as a game‐changing approach in oncology drug development. It represents a paradigm shift from traditional enzyme inhibition to selective protein degradation.
Mohamed S. Nafie, Mohamed K. Diab, Asmaa S. A. Yassen, Amany M. Elshamy, Mohamed R. El Tohamy, Haytham O. Tawfik, Sherif Ashraf Fahmy   +6 more
wiley   +1 more source

Progression and Metastasis of Lung Cancer: Clinical Features, Molecular Mechanisms, and Clinical Managements

MedComm, Volume 6, Issue 12, December 2025.
Lung cancer represents a significant global health threat. Despite progress in treatment, metastasis continues to present a major clinical challenge. This article reviews the metastases of lung cancer to the liver, bone, and brain, focusing on clinical symptoms, molecular mechanisms, and treatment strategies.
Yunkui Zhang, Meixi Chen, Xumeng Fang, Yu Han, Yingke Li   +4 more
wiley   +1 more source

Rapidly Growing ALK‐Negative NTRK3‐Positive Inflammatory Myofibroblastic Tumour of the Lung

Respirology Case Reports, Volume 13, Issue 12, December 2025.
This report describes the importance of comprehensive molecular testing in anaplastic lymphoma kinase‐negative inflammatory myofibroblastic tumour (IMT) and demonstrates that complete surgical resection can achieve excellent outcomes even in rapidly growing IMT.
Yukitaka Sato, Fumitsugu Kojima, Takeshi Ushigusa, Shinsaku Kabemura, Torahiko Jinta, Toru Bando   +5 more
wiley   +1 more source

Alectinib combined with VRCD and BV monoclonal antibody for the treatment of ALK-positive large B-cell lymphoma: a case report and literature review

Frontiers in Oncology
We report a case of a 53-year-old male patient who was diagnosed with anaplastic lymphoma kinase-positive large B-cell lymphoma. A pathological examination showed plasma-cell immunophenotype negative for mature B-lymphocyte markers.
Hongxia Wang, Junjun Bai, Bei Zhang, Z. Pei, Yingxin Zhao, Jingjing Gu, Zhiyu Fang, Miaomiao Liu, Xun Liang, Qinglin Song   +9 more
semanticscholar   +1 more source

Patients with high-grade alectinib-induced skin rash: How do we desensitize these patients? A case report and review of literature

SAGE Open Medical Case Reports, 2020
With the advent of targeted therapy for non-small-cell lung cancer, there are many new available treatment options for patients whose cancer harbors an actionable mutation or alteration.
Karan Seegobin, Umair Majeed, Yanyan Lou, Yujie Zhao, Rami Manochakian   +4 more
doaj   +1 more source